---
title: "Chimin: Net profit loss of 52.6959 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253773280.md"
description: "Chimin announced that its operating revenue in the first half of 2025 was 366 million yuan, a year-on-year decrease of 21.30%. The net profit loss was 52.6959 million yuan, compared to a net profit of 25.445 million yuan in the same period last year. During the reporting period, the company will not distribute profits or convert capital reserves into share capital"
datetime: "2025-08-20T09:01:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253773280.md)
  - [en](https://longbridge.com/en/news/253773280.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253773280.md)
generator: "portal-rs"
---

# Chimin: Net profit loss of 52.6959 million yuan in the first half of 2025

Chimin announced that in the first half of 2025, operating revenue was 366 million yuan, a year-on-year decrease of 21.30%. The net profit was a loss of 52.6959 million yuan, compared to a net profit of 25.445 million yuan in the same period last year. During the reporting period, the company will not distribute profits or convert capital reserves into share capital

### Related Stocks

- [603222.CN](https://longbridge.com/en/quote/603222.CN.md)

## Related News & Research

- [Viromed Medical’s Heike Perbandt, closely associated with managing body member Uwe Perbandt, sells shares for EUR 52,000](https://longbridge.com/en/news/298227013.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [SynAct Pharma outlines Phase 3-ready resomelagon strategy in rheumatoid arthritis presentation](https://longbridge.com/en/news/298283288.md)
- [Cyclezyme to buy Ragn-Sells melanin patent, pays via shares for 7.9% stake](https://longbridge.com/en/news/298137821.md)
- [Vytrus Biotech says European skin rejuvenation patent validated in seven countries](https://longbridge.com/en/news/298226256.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**